Showing posts with label DaVita. Show all posts
Showing posts with label DaVita. Show all posts

Monday, April 7, 2014

The Motley Fool: Can DaVita HealthCare Partners Inc's Run Last?

The two largest hemodialysis service providers, Fresenius Medical Care (NYSE: FMS  ) and DaVita HealthCare Partners (NYSE: DVA  ) , may have a lot in common, but the performance of their shares is not one of them. Over the past year, DaVita has a 10% lead on on Fresenius and that lead only increases at the two-year (roughly 60%), and five-year (nearly 120%) marks.

Though the operating margins have been similar, DaVita has significantly outgrown Fresenius over the past decade and generated more free cash flow as a percentage of revenue. Better still, DaVita's HealthCare Partners business looks like a "right place, right time, right idea" operation that can benefit from a growing focus on basing health care spending on outcomes, not procedures. Considering DaVita's growth potential, the shares may yet be as much as 20% undervalued today.

Continue here:
Can DaVita HealthCare Partners Inc's Run Last?

Wednesday, April 2, 2014

The Motley Fool: Can Fresenius Medical Care AG & Co. Get Past Medicare Reimbursement Issues?

When Medicare plays a major role in a company's business model there always seem to be challenges. Such is the case for Fresenius Medical Care (NYSE: FMS  ) . While the company's strong global share in dialysis equipment and strong share in North American dialysis services ought to be a strong positive in the company's favor, the difficult reimbursement environment has created challenges and uncertainties in the company's model. Though there is a significant global growth in the number of patients with end-stage renal disease, Fresenius Medical Care can't afford to drop the ball when it comes to careful expense management.

Read more here:
Can Fresenius Medical Care AG & Co. Get Past Medicare Reimbursement Issues?

Tuesday, November 27, 2012

Investopedia: Will Baxter Go For Gambro?

When real news fade, rumors seem to crop up a little more readily. In the case of the rumor that Baxter (NYSE:BAX) is arranging a bid for Gambro, however, there's a little more credibility than usual. Baxter has long wanted Gambro, and the combination would make sense in a med-tech market where growth is increasingly hard to come by.

For the full article please continue here:
http://www.investopedia.com/stock-analysis/2012/Will-Baxter-Go-For-Gambro-BAX-FMS-NXTM-DVA1126.aspx